胃癌分子靶向治疗研究新进展  

Advances in molecular-targeted therapies for gastric cancer and gastroesophageal junction adenocarcinoma

作　　者：黎军和[1] 熊建萍[1] 

机构地区：[1]南昌大学第一附属医院肿瘤科,南昌市330006

出　　处：《中国肿瘤临床》2015年第23期1118-1123,共6页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81441083)资助~~

摘　　要：进展期胃癌及胃食管连接部（gastroesophageal junction,GEJ）腺癌的预后差。与最佳支持治疗相比,化疗能够延长患者生存期,改善生存质量,但单纯化疗患者中位生存期（median survival）仅为7~10个月。近年随着对胃癌发病分子机制的深入了解,多种靶向关键信号传导途径的分子靶向治疗药物进行了国际多中心临床研究,改变了胃癌的治疗模式。To GA研究显示靶向HER-2（human epidermal growth factor receptor 2,HER-2）的单克隆抗体曲妥珠单抗联合化疗可使HER-2阳性的进展期胃癌患者OS达13.8个月。此外,多项靶向胃癌血管生成、c-Met、PARP、免疫治疗的临床研究正在进行中,本文对近年胃癌及GEJ腺癌分子靶向治疗的研究现状进行综述。The prognosis of advanced gastric cancer and gastroesophageal junction （GEJ） adenocarcinoma is poor. Although che- motherapy prolongs patient survival and improves quality of life to a greater extent best supportive care compared to, the median over- survival of patients with advanced gastric cancer is limited to approximately 7-10 months. With remarkable progress in the understand- ing of molecular mechanisms, molecular-targeted agents have been developed and evaluated in international randomized phase Ⅲ clini- cal trials. These agents may change the treatment mode of this disease. A ToGA study initially demonstrated that the trastuzumab, the monoclonal antibody of HER-2, as a molecular-targeted agent, in combination with chemotherapy, can prolong the overall survival of patients to 13.8 months. Several agents targeting angiogenesis, c-Met, PARP, and immunotherapy are currently subjected to clinical tri- als. This review summarizes the current status of molecular-targeted therapies for gastric cancer and GEJ adenocarcinoma.

关 键 词：胃癌 胃食管连接部腺癌 靶点 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]